These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Complementation analysis in patients with the clinical phenotype of a generalised peroxisomal disorder. Steinberg SJ; Fensom AH J Med Genet; 1996 Apr; 33(4):295-9. PubMed ID: 8730284 [TBL] [Abstract][Full Text] [Related]
46. [Liver pathologies due to peroxisome disorders]. Lovisetto P; Raviolo P Recenti Prog Med; 1994 Feb; 85(2):134-41. PubMed ID: 8184191 [TBL] [Abstract][Full Text] [Related]
47. Neonatal seizures and retardation in a girl with biochemical features of X-linked adrenoleukodystrophy: a possible new peroxisomal disease entity. Naidu S; Hoefler G; Watkins PA; Chen WW; Moser AB; Hoefler S; Rance NE; Powers JM; Beard M; Green WR Neurology; 1988 Jul; 38(7):1100-7. PubMed ID: 3386829 [TBL] [Abstract][Full Text] [Related]
48. Adrenoleukodystrophy--early ultrastructural changes in the brain. Takeda S; Ohama E; Ikuta F Acta Neuropathol; 1989; 78(2):124-30. PubMed ID: 2750483 [TBL] [Abstract][Full Text] [Related]
49. In situ genetic complementation analysis of cells with generalized peroxisomal dysfunction. Singh AK; Kulvatunyou N; Singh I; Stanley WS Hum Hered; 1989; 39(5):298-301. PubMed ID: 2482247 [TBL] [Abstract][Full Text] [Related]
50. [Peroxisomes and peroxisomal diseases]. Petelenz M; Gonciarz Z; Grzybek H; Panz B Postepy Hig Med Dosw; 1991; 45(1-2):77-99. PubMed ID: 1717967 [TBL] [Abstract][Full Text] [Related]
51. Complementation study of peroxisome-deficient disorders by immunofluorescence staining and characterization of fused cells. Yajima S; Suzuki Y; Shimozawa N; Yamaguchi S; Orii T; Fujiki Y; Osumi T; Hashimoto T; Moser HW Hum Genet; 1992 Mar; 88(5):491-9. PubMed ID: 1372585 [TBL] [Abstract][Full Text] [Related]
52. Disorders related to the metabolism of phytanic acid. Stokke O; Skjeldal OH; Høie K Scand J Clin Lab Invest Suppl; 1986; 184():3-10. PubMed ID: 2438746 [TBL] [Abstract][Full Text] [Related]
53. Clinical and biochemical heterogeneity in conditions with phytanic acid accumulation. Skjeldal OH; Stokke O; Refsum S; Norseth J; Petit H J Neurol Sci; 1987 Jan; 77(1):87-96. PubMed ID: 2433405 [TBL] [Abstract][Full Text] [Related]
56. Restoring the DHA levels in the brains of Zellweger patients. Martinez M J Mol Neurosci; 2001; 16(2-3):309-16; discussion 317-21. PubMed ID: 11478386 [TBL] [Abstract][Full Text] [Related]
57. Clinicopathological study of Refsum's disease with particular reference to fatal complications. Allen IV; Swallow M; Nevin NC; McCormick D J Neurol Neurosurg Psychiatry; 1978 Apr; 41(4):323-32. PubMed ID: 77310 [TBL] [Abstract][Full Text] [Related]
58. [Peroxisomal disorders--elucidation of another group of degenerative diseases]. Svatý J Cesk Pediatr; 1988 Apr; 43(4):230-5. PubMed ID: 2456159 [No Abstract] [Full Text] [Related]
59. Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review. Ogaki K; Koga S; Aoki N; Lin W; Suzuki K; Ross OA; Dickson DW Neuropathology; 2016 Feb; 36(1):64-76. PubMed ID: 26227820 [TBL] [Abstract][Full Text] [Related]
60. Peroxisomal very long-chain fatty acid beta-oxidation in human skin fibroblasts: activity in Zellweger syndrome and other peroxisomal disorders. Wanders RJ; van Roermund CW; van Wijland MJ; Heikoop J; Schutgens RB; Schram AW; Tager JM; van den Bosch H; Poll-Thé BT; Saudubray JM Clin Chim Acta; 1987 Jul; 166(2-3):255-63. PubMed ID: 2441904 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]